Work Here?
Overview
Caribou Biosciences develops allogeneic CAR-T cell therapies using a CRISPR-based chRDNA platform (Cas9 and Cas12a) to create precise genome edits. Its lead approach centers on off-the-shelf, armored CAR-T cells designed to persist longer and resist exhaustion, including PD-1 knockout, enabling rapid access for patients. The company advances wholly-owned programs and collaborates with pharma partners, such as AbbVie, to push its therapies through clinical development. Its goal is to bring regulated, off-the-shelf CAR-T therapies to patients with hematologic cancers and autoimmune diseases and to reach commercialization, supported by funding through at least 2027.
About Caribou Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Berkeley, California
Founded
2011
Simplify's Take
What believers are saying
- CB-011 receives FDA RMAT designation on March 31, 2026.
- $10 million revenue from 2024 licensing deals fuels pipeline.
- Capital funds operations through second half of 2027.
What critics are saying
- CRISPR Therapeutics' CTX112 achieves 85% ORR, surpassing CB-010's 60%.
- Allogene's ALLO-501A gains FDA approval by Q2 2026, seizing 40% market.
- Quarterly $120M cash burn exhausts funds by Q1 2027.
What makes Caribou Biosciences unique
- chRDNA platform uses hybrid RNA-DNA guides for superior CRISPR specificity.
- Cas12a and Cas9 technologies enable precise allogeneic CAR-T edits.
- Founders include Nobel laureate Jennifer Doudna and Rachel Haurwitz.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$618.6M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Tuition Reimbursement
Generous paid vacation time
Comprehensive compensation package
ESPP
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -4%2 year growth
↑ 5%Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025.
Mr. O'Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO, leading the finance, investor relations, corporate communications, IT, procurement, and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease.
Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer.
Caribou Biosciences is cutting its CAR-NK research and laying off 21 employees, or 12% of its staff, the company announced Tuesday.
Caribou Biosciences announces appointment of Terri Laufer, MD, to its scientific advisory board.
Caribou Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Caribou Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Berkeley, California
Founded
2011
Caribou Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today